Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
Oragenics (NYSE American: OGEN), a biotechnology company focused on innovative treatments for concussion and brain-related health conditions, has filed its Annual Report on Form 10-K for the year ended December 31, 2024. The filing, submitted to the SEC on March 14, 2025, received an unqualified audit opinion from its independent registered public accounting firm.
However, the audit included an explanatory paragraph regarding the company's ability to continue as a going concern. The company states its commitment to advancing its pipeline, exploring strategic opportunities, and securing resources for long-term growth. Further details are available in Footnote 1 of the consolidated financial statements.
Oragenics (NYSE American: OGEN), una società biotecnologica focalizzata su trattamenti innovativi per le commozioni cerebrali e le condizioni di salute correlate al cervello, ha presentato il suo Rapporto Annuale sul Modulo 10-K per l'anno conclusosi il 31 dicembre 2024. La presentazione, inviata alla SEC il 14 marzo 2025, ha ricevuto un'opinione di revisione senza riserve da parte della sua società di revisione contabile indipendente registrata.
Tuttavia, la revisione ha incluso un paragrafo esplicativo riguardante la capacità dell'azienda di continuare come entità in funzionamento. L'azienda dichiara il suo impegno a far progredire il proprio portafoglio, esplorare opportunità strategiche e assicurare risorse per una crescita a lungo termine. Ulteriori dettagli sono disponibili nella Nota 1 delle situazioni finanziarie consolidate.
Oragenics (NYSE American: OGEN), una empresa de biotecnología centrada en tratamientos innovadores para las conmociones cerebrales y las condiciones de salud relacionadas con el cerebro, ha presentado su Informe Anual en el Formulario 10-K para el año que terminó el 31 de diciembre de 2024. La presentación, enviada a la SEC el 14 de marzo de 2025, recibió una opinión de auditoría sin salvedades de su firma de contabilidad pública registrada e independiente.
Sin embargo, la auditoría incluyó un párrafo explicativo sobre la capacidad de la empresa para continuar como una entidad en funcionamiento. La empresa afirma su compromiso de avanzar en su cartera, explorar oportunidades estratégicas y asegurar recursos para el crecimiento a largo plazo. Más detalles están disponibles en la Nota 1 de los estados financieros consolidados.
오라제닉스 (NYSE American: OGEN), 뇌진탕 및 뇌 관련 건강 문제를 위한 혁신적인 치료에 중점을 둔 생명공학 회사가 2024년 12월 31일로 종료된 연도의 10-K 양식 연례 보고서를 제출했습니다. 이 보고서는 2025년 3월 14일 SEC에 제출되었으며, 독립 등록 공인 회계법인으로부터 무자격 감사 의견을 받았습니다.
그러나 감사에는 회사의 지속 기업으로서의 능력에 대한 설명 단락이 포함되었습니다. 회사는 파이프라인을 발전시키고 전략적 기회를 탐색하며 장기 성장을 위한 자원을 확보하겠다는 의지를 표명했습니다. 더 많은 세부정보는 연결 재무제표의 주석 1에서 확인할 수 있습니다.
Oragenics (NYSE American: OGEN), une entreprise de biotechnologie axée sur des traitements innovants pour les commotions cérébrales et les problèmes de santé liés au cerveau, a déposé son Rapport Annuel sur le Formulaire 10-K pour l'année se terminant le 31 décembre 2024. Le dépôt, soumis à la SEC le 14 mars 2025, a reçu un avis d'audit sans réserve de la part de son cabinet d'audit public indépendant enregistré.
Cependant, l'audit comprenait un paragraphe explicatif concernant la capacité de l'entreprise à continuer en tant qu'entité en activité. L'entreprise déclare son engagement à faire progresser son pipeline, à explorer des opportunités stratégiques et à sécuriser des ressources pour une croissance à long terme. D'autres détails sont disponibles dans la Note 1 des états financiers consolidés.
Oragenics (NYSE American: OGEN), ein Biotechnologieunternehmen, das sich auf innovative Behandlungen von Gehirnerschütterungen und gehirnbezogenen Gesundheitszuständen konzentriert, hat seinen Jahresbericht im Formular 10-K für das am 31. Dezember 2024 endende Jahr eingereicht. Die Einreichung, die am 14. März 2025 bei der SEC eingereicht wurde, erhielt ein uneingeschränktes Prüfungsurteil von ihrer unabhängigen registrierten Wirtschaftsprüfungsgesellschaft.
Die Prüfung beinhaltete jedoch einen erläuternden Absatz zur Fähigkeit des Unternehmens, als fortführender Betrieb zu agieren. Das Unternehmen erklärt sein Engagement, sein Produktportfolio voranzutreiben, strategische Möglichkeiten zu erkunden und Ressourcen für langfristiges Wachstum zu sichern. Weitere Einzelheiten sind in Fußnote 1 der konsolidierten Finanzberichte verfügbar.
- Received unqualified audit opinion on consolidated financial statements
- Received going concern warning in audit report, indicating substantial doubt about company's ability to continue operations
- Company likely facing significant financial challenges requiring additional funding
SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025.
The Company’s audited consolidated financial statements received an unqualified audit opinion from its independent registered public accounting firm. As part of the audit, an explanatory paragraph was included regarding the Company’s ability to continue as a going concern. Oragenics remains committed to advancing its innovative pipeline, exploring strategic opportunities, and securing the necessary resources to support its long-term growth. Additional details can be found in Footnote 1 of the consolidated financial statements included in the filing.
About Oragenics:
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Investor Contact
Rich Cockrell
Investor Relations
404.736.3838
OGEN@CG.CAPITAL
FAQ
What did the 2024 audit report reveal about Oragenics (OGEN) financial status?
When did Oragenics (OGEN) file its 2024 Annual Report?
What is the current focus of Oragenics (OGEN) business?
What strategic steps is OGEN taking to address its financial concerns?
